Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 19/20 | 0.67 |
| ▸ | SLC6A2 known ✓ | P23975 | 19/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL4482407 | 1.00 | SLC6A4 (0.67) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4486778 | 0.90 | SLC6A4 (0.61) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL5815530 | 0.90 | SLC6A4 (0.61) | SLC6A4SLC6A2SLC6A3 | |
| Fumaric Acid SCHEMBL4493089 | 0.89 | SLC6A2 (0.71) | SLC6A4SLC6A2SLC6A3 | |
| Fumaric Acid SCHEMBL4493084 | 0.89 | SLC6A2 (0.71) | SLC6A4SLC6A2SLC6A3 | |
| Fumaric Acid SCHEMBL4491779 | 0.87 | SLC6A2 (0.54) | SLC6A4SLC6A2SLC6A3 | |
| Fumaric Acid SCHEMBL4491783 | 0.87 | SLC6A2 (0.54) | SLC6A4SLC6A2SLC6A3 | |
| Fumaric Acid SCHEMBL4693202 | 0.83 | SLC6A2 (0.53) | SLC6A4SLC6A2SLC6A3 | |
| Fumaric Acid SCHEMBL4491704 | 0.83 | SLC6A2 (0.53) | SLC6A4SLC6A2SLC6A3 | |
| Fumaric Acid SCHEMBL4492719 | 0.82 | SLC6A2 (0.53) | SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7619096-B2 | 3-Aminopyrrolidines as inhibitors of monoamine uptake | ELI LILLY AND COMPANY (US) | 2009-11-17 | — | — | US | disclosed |
| US-20060270713-A1 | 3-Aminopyrrolidines as inhibitors of monoamine uptake | ELI LILLY AND COMPANY | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270713-A1 | 3-Aminopyrrolidines as inhibitors of monoamine uptake | SLC6A2, SLC6A3, SLC18A2 | SLC6A4 5/4885SLC6A2 1/4885SLC6A3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.